Esofly-L Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Esomeprazole 40 mg, designed to manage gastrointestinal disorders effectively. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates gastrointestinal motility by enhancing gastric emptying and improving esophageal sphincter tone, making it beneficial in conditions such as functional dyspepsia, gastroesophageal reflux disease (GERD), and diabetic gastroparesis. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby providing symptomatic relief and promoting mucosal healing in acid-related disorders. The combination therapy addresses both motility dysfunction and acid hypersecretion, offering comprehensive management of upper gastrointestinal symptoms including heartburn, regurgitation, and epigastric discomfort. The sustained-release mechanism ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and clinical efficacy. Esofly-L Capsule SR should be administered as prescribed, typically before meals, and is contraindicated in patients with known hypersensitivity to its components. Caution is advised in individuals with hepatic or renal impairment. Potential adverse effects may include headache, dizziness, and gastrointestinal disturbances. Clinical monitoring is recommended to optimize treatment outcomes and minimize risks.